Cantor Fitzgerald Reaffirms "Overweight" Rating for Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report)'s stock had its "overweight" rating restated by equities research analysts at Cantor Fitzgerald in a note issued to investors on Thursday,Benzinga reports. They presently have a $30.00 price target on the biotechnology company's stock. Cantor Fitzgerald's price objective points to a potential upside of 125.90% from the stock's current price.

Separately, HC Wainwright reaffirmed a "buy" rating and set a $77.00 price target on shares of Capricor Therapeutics in a research report on Monday, March 17th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to MarketBeat, Capricor Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $34.50.

Capricor Therapeutics Stock Performance

CAPR stock traded up $0.42 during trading on Thursday, reaching $13.28. 803,938 shares of the company traded hands, compared to its average volume of 1,386,414. The business has a 50 day simple moving average of $14.07 and a 200 day simple moving average of $14.76. Capricor Therapeutics has a 12 month low of $3.52 and a 12 month high of $23.40. The company has a market capitalization of $603.84 million, a price-to-earnings ratio of -12.53 and a beta of 4.10.

Remove Ads

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.15. The business had revenue of $11.13 million for the quarter, compared to analysts' expectations of $9.87 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. As a group, research analysts forecast that Capricor Therapeutics will post -1.21 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CAPR. Summit Investment Advisors Inc. grew its holdings in shares of Capricor Therapeutics by 54.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock valued at $53,000 after buying an additional 1,345 shares during the last quarter. Russell Investments Group Ltd. lifted its position in Capricor Therapeutics by 172.8% during the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock worth $64,000 after acquiring an additional 2,947 shares during the period. Virtus ETF Advisers LLC purchased a new stake in Capricor Therapeutics during the 4th quarter valued at about $68,000. AlphaQuest LLC acquired a new position in shares of Capricor Therapeutics in the fourth quarter valued at about $78,000. Finally, New York State Common Retirement Fund raised its stake in shares of Capricor Therapeutics by 625.0% in the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock worth $80,000 after purchasing an additional 5,000 shares during the last quarter. Institutional investors and hedge funds own 21.68% of the company's stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.